NKGen Biotech, Inc. (NKGN)

OTCMKTS · Delayed Price · Currency is USD

0.0120

0.00 (0.00%)

Sep 29, 2026, 11:12 AM EST

NKGen Biotech Employees

NKGen Biotech had 26 employees as of December 31, 2024. The number of employees decreased by 37 or -58.73% compared to the previous year.

Employees

26

Change (1Y)

-37

Growth (1Y)

-58.73%

Revenue / Employee

n/a

Profits / Employee

-$905,923

Market Cap

1.57M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2024	26	-37	-58.73%
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
Evofem Biosciences	29
AXIM Biotechnologies	7
AccuStem Sciences	4
Abpro Holdings	3
Bioxytran	2
Avenue Therapeutics	1

Employee Rankings

NKGen Biotech News

14 days ago - NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum - GlobeNewsWire
19 days ago - NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 - GlobeNewsWire
2 months ago - NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions - GlobeNewsWire
4 months ago - NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment - GlobeNewsWire
5 months ago - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - GlobeNewsWire
6 months ago - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ - GlobeNewsWire
6 months ago - NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026 - GlobeNewsWire
8 months ago - NKGen Biotech appoints Bruce Miller to Scientific Advisory Board - TheFly